Tenax Therapeutics, Inc. (TENX): Operating Income
-$56.38M
Year ended 2025-12-31
-$68.61M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$56.38M | n/m | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | -$19.49M | n/m | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | -$8.23M | n/c | 2025-03-25, From 2023-01-01 |
| 2022-12-31 | $11.05M | n/c | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | -$32.73M | n/c | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $9.87M | n/c | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | -$8.56M | n/m | 2021-04-16, From 2019-01-01 |
| 2018-12-31 | -$6.89M | n/m | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | -$9.21M | n/m | 2019-04-01, From 2017-01-01 |
| 2016-12-31 | -$52.65M | n/a | 2018-04-02, From 2016-01-01 |
| No annual figure between 2015-04-30 and 2016-12-31. | |||
| 2015-04-30 | -$14.82M | n/m | 2017-03-16, From 2014-05-01 |
| 2014-04-30 | -$16.61M | n/m | 2017-03-16, From 2013-05-01 |
| 2013-04-30 | -$5.19M | n/m | 2014-07-29, From 2012-05-01 |
| 2012-04-30 | -$8.22M | n/c | 2013-06-26, From 2011-05-01 |
| 2011-04-30 | $10.56M | n/a | 2012-07-25, From 2010-05-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Tenax Therapeutics, Inc. (TENX) | 2025-12-31 | -$56.38M | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.05B | +18.0% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | -$4.39M | n/m |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $24.74M | +23.1% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | -$5.29M | n/m |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | -$18.21M | n/m |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$2.54M | n/m |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $2.16B | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $231.0K | n/m |
Compare TENX, ABT, TXMD, NATR side by side · Screen every company in Pharmaceutical Preparations ↗